Artificial intelligence (AI) and psychedelic medicines are among the most high-profile evolving disruptive innovations within mental healthcare in recent years. Although AI and psychedelics may not have historically shared any common ground, there exists the potential for these subjects to combine in generating innovative mental health treatment approaches. In order to inform our perspective, we conducted a scoping review of relevant literature up to late August 2024 via PubMed intersecting AI with psychomedical use of psychedelics. Our perspective covers the potential application of AI in psychedelic medicine for: drug discovery and clinical trial optimization (including pharmacodynamics); study design; understanding psychedelic experiences; personalization of treatments; clinical screening, delivery, and follow-up (potentially delivered via chatbots/apps); application of psychological preparation, integration, and general mental health support; its role in enhancing treatment via brain modulatory devices (including virtual reality and haptic suits); and the consideration of ethical and security safeguards. Challenges include the need for sufficient data protection and security, and a range of necessary ethical protections. Future avenues of exploration could involve directly administering psychedelics (or providing algorithm-generated effects) to inorganic AI-interfaced neural networks that may exceed human brain activity (i.e., cognitive capacity) and intelligence.

中文翻译：

---

人工智能和迷幻药


人工智能 （AI） 和迷幻药是近年来精神保健领域最引人注目的不断发展的颠覆性创新之一。尽管人工智能和迷幻药在历史上可能没有任何共同点，但这些主题有可能结合起来产生创新的心理健康治疗方法。为了告知我们的观点，我们通过 PubMed 对截至 2024 年 8 月下旬的相关文献进行了范围界定审查，将人工智能与迷幻药的心理医学用途相交。我们的观点涵盖了人工智能在迷幻药中的潜在应用，包括：药物发现和临床试验优化（包括药效学）;研究设计;了解迷幻体验;个性化治疗;临床筛查、交付和随访（可能通过聊天机器人/应用程序提供）;应用心理准备、整合和一般心理健康支持;它在通过大脑调节设备（包括虚拟现实和触觉套装）增强治疗中的作用;以及对道德和安全保障措施的考虑。挑战包括需要足够的数据保护和安全性，以及一系列必要的道德保护。未来的探索途径可能涉及直接对可能超过人脑活动（即认知能力）和智力的无机 AI 接口神经网络施用迷幻药（或提供算法生成的效果）。